Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 October 2005Website:
http://www.nanoviricides.comNext earnings report:
14 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | 27 min agoDividend
Analysts recommendations
Institutional Ownership
NNVC Latest News
NanoViricides (NYSE-A:NNVC) reported progress on its lead antiviral drug NV-387 and revealed plans to advance Phase II clinical trials for MPox and RSV. The Shelton, Connecticut-based company is waiting for results from its Phase I trial of NV-387 and has taken steps towards starting a Phase II trial of NV-387 for the treatment of MPox infection in Central Africa.
SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024 with the Securities and Exchange Commission (SEC) on Thursday, November 14, 2024. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057824001991/nnvc-20240930x10q.htm).
SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.
SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.
Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.
NanoViricides (NYSE-A:NNVC) filed its annual report, announcing that its broad-spectrum antiviral NV-387 is progressing to Phase II clinical trials, with potential indications including RSV, influenza, MPOX/smallpox, and COVID-19. NV-387 has demonstrated broad-spectrum efficacy in preclinical trials against viruses such as COVID-19, RSV, and influenza.
SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2024 with the Securities and Exchange Commission (SEC) on Friday, September 27, 2024. The report can be accessed at the SEC website ( https://www.sec.gov/ix?doc=/Archives/edgar/data/1379006/000141057824001650/nnvc-20240630x10k.htm ).
NanoViricides (NYSE-A:NNVC) announced that it has signed a Memorandum of Understanding (MOU) with TheraCour Pharma, granting it the right of first refusal on all antiviral drug developments. This agreement expands NanoViricides (NYSE-A:NNVC)' access to critical intellectual property, enhancing its ability to develop treatments for a wide range of viral infections.
SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it has now obtained a right of first refusal (ROFR) for all antiviral drug developments from the R&D firm TheraCour Pharma, Inc. ("TheraCour").
NanoViricides (NYSE-A:NNVC) CEO Anil Diwan joined Proactive to discuss the promise of its lead drug NV-387 as a broad-spectrum antiviral. Diwan explained that NV-387, a host mimetic drug, works differently from traditional antiviral treatments by mimicking a natural cellular feature, making it difficult for viruses to escape.
What type of business is NanoViricides?
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
What sector is NanoViricides in?
NanoViricides is in the Healthcare sector
What industry is NanoViricides in?
NanoViricides is in the Biotechnology industry
What country is NanoViricides from?
NanoViricides is headquartered in United States
When did NanoViricides go public?
NanoViricides initial public offering (IPO) was on 26 October 2005
What is NanoViricides website?
https://www.nanoviricides.com
Is NanoViricides in the S&P 500?
No, NanoViricides is not included in the S&P 500 index
Is NanoViricides in the NASDAQ 100?
No, NanoViricides is not included in the NASDAQ 100 index
Is NanoViricides in the Dow Jones?
No, NanoViricides is not included in the Dow Jones index
When was NanoViricides the previous earnings report?
No data
When does NanoViricides earnings report?
The next expected earnings date for NanoViricides is 14 February 2025